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AbsTRACT
Objectives To inform the 2019 update of the 
european league against Rheumatism (eUlAR) 
recommendations for the management of rheumatoid 
arthritis (RA).
Methods A systematic literature research (slR) 
to investigate the efficacy of any disease- modifying 
antirheumatic drug (DMARD) (conventional synthetic 
(cs)DMARD, biological (b) and biosimilar DMARD, 
targeted synthetic (ts)DMARD) or glucocorticoid (GC) 
therapy in patients with RA was done by searching 
MeDline, embase and the Cochrane library for articles 
published between 2016 and 8 March 2019.
Results 234 abstracts were selected for detailed 
assessment, with 136 finally included. They comprised 
the efficacy of bDMARDs versus placebo or other 
bDMARDs, efficacy of Janus kinase (JAK) inhibitors 
(JAKi) across different patient populations and 
head- to- head of different bDMARDs versus JAKi or 
other bDMARDs. switching of bDMARDs to other 
bDMARDs or tsDMARDs, strategic trials and tapering 
studies of bDMARDs, csDMARDs and JAKi were 
assessed. The drugs evaluated included abatacept, 
adalimumab, ABT-122, baricitinib, certolizumab 
pegol, sBi-087, CnTO6785, decernotinib, etanercept, 
filgotinib, golimumab, GCs, Gs-9876, guselkumab, 
hydroxychloroquine, infliximab, leflunomide, 
mavrilimumab, methotrexate, olokizumab, otilimab, 
peficitinib, rituximab, sarilumab, salazopyrine, 
secukinumab, sirukumab, tacrolimus, tocilizumab, 
tofacitinib, tregalizumab, upadacitinib, ustekinumab 
and vobarilizumab. The efficacy of many bDMARDs 
and tsDMARDs was shown. switching to another 
tumour necrosis factor inhibitor (TnFi) or non- TnFi 
bDMARDs after TnFi treatment failure is efficacious. 
Tapering of DMARDs is possible in patients achieving 
long- standing stringent clinical remission; in patients 
with residual disease activity (including patients 
in lDA) the risk of flares is increased during the 
tapering. Biosimilars are non- inferior to their reference 
products.
Conclusion This slR informed the task force 
regarding the evidence base of various therapeutic 
regimen for the development of the update of eUlAR’s 
RA management recommendation.
InTROduCTIOn
To provide the task force on the 2019 update 
of the European League against Rheumatism 
(EULAR) recommendations for the pharmacolog-
ical management of rheumatoid arthritis (RA) with 
all available evidence that had emerged since the 
last update, systematic literature researches (SLRs) 
Key messages
What is already known about this subject?
 ► Since the 2016 update of the recommendations 
for the management of rheumatoid arthritis 
(RA), the body of evidence has grown vividly. 
Therefore, this systematic literature research 
(SLR) was performed to inform the 2019 
European League against Rheumatism (EULAR) 
task force with the summarised evidence 
on efficacy of conventional and targeted 
synthetic disease- modifying antirheumatic 
drugs (DMARDs), biological DMARDs and 
glucocorticoids.
What does this study add?
 ► Trials comparing biological DMARDs have 
shown similar efficacy, regardless of the 
underlying mode of action.
 ► Head- to- head trials between Janus kinase (JAK) 
inhibitors (JAKi) and tumour necrosis factor 
inhibitor inhibitors did not reveal clinically 
important differences in efficacy.
 ► Drug tapering of DMARDs, including JAKi is 
possible, especially in patients achieving stable 
remission.
 ► Treating patients to target using MRI- defined 
remission does not lead to better outcomes 
when compared with a conventional clinical 
treat- to- target strategy.
How might this impact on clinical practice or 
future developments?
 ► This SLR, alongside with the safety SLR, 
provided the 2019 EULAR RA management 
recommendations task force with the emerged 
evidence since 2016.
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were performed. In 2016, three SLRs were conducted assessing 
efficacy of biological disease- modifying antirheumatic drugs 
(bDMARDs),1 efficacy of glucocorticoids (GCs), conventional 
synthetic (cs) and targeted synthetic (ts) DMARDs,2 and safety of 
pharmacological treatments in RA.3 The 2019 update was based 
on two SLRs, one on safety and the present one on efficacy of 
pharmacological interventions in RA.
The body of evidence has grown vividly in the last 3 years, 
especially regarding tsDMARDs inhibiting Janus Kinase inhib-
itor (JAKi), novel bDMARDs targeting new as well as established 
pathways and trials comparing bDMARDs to other bDMARDs 
or tsDMARDs, providing important information on the compar-
ative efficacy of these compounds.4 Further, studies on tapering 
and stopping treatment broaden the information base for rheu-
matologists and patients on the question of possible disease 
flares after tapering or cessation of drugs, once patients have 
reached the clinical target. Strategic studies on how to optimally 
treat patients to target,5 using clinical and imaging targets have 
also answered important research questions.6 Finally, a large 
number of trials compared the efficacy and safety of biosimilars 
(bs) DMARDs with those of their bio- originators (bo), including 
switching between boDMARD and respective bsDMARDs.
This SLR was conducted to update the evidence on efficacy of 
pharmacological interventions in RA. This involves the evidence 
accrued since the last update of the treatment recommendations 
for RA, published by EULAR in 2016.7 Another SLR focusing 
on safety of pharmacological treatments in RA is published 
separately.8
MeTHOds
The EULAR updated standard operating procedures were 
followed,9 and an SLR protocol was developed and approved by 
the steering committee.
Studies eligible for inclusion in this SLR were randomised, 
controlled, double- blind trials investigating csDMARDs, 
bDMARDs (bo and bsDMARDs), tsDMARDs or GCs in adult 
patients with RA classified according to the 2010 American 
College of Rheumatology (ACR)/EULAR or the ACR 1987 
criteria. This SLR was considered to further update the available 
evidence since the previous SLRs, therefore, articles published 
between 1 January 2016 and 8 March 2019 with no language 
restriction were searched. Additionally, studies presented as 
conference abstracts at the EULAR and ACR annual meetings 
from 2016 to 2018 were also eligible for inclusion. References of 
original articles published on submission of the manuscript (after 
the data cut), but with respective conference abstracts included 
before, were included in the reference list.
The initial literature search was conducted by an experienced 
librarian (LF) using Medline, Embase, The Cochrane CENTRAL 
Register of Controlled Trials (Central) and the EULAR/ACR 
abstract archives as information sources. The detailed search 
strategy for each database is shown in the online supplementary 
tables S1.1–S1.6.
The study selection process was conducted independently by 
two investigators (AK and AS) and discussed until agreement was 
achieved. A senior methodologist (RL) was consulted in the case 
of uncertainties. After the initial title and abstract screening for 
identification of reports of potential interest, a detailed assess-
ment for eligibility of preselected articles was done. Data of 
eligible studies were extracted based on standardised methods 
using pivotal forms. Variables of interest were predefined in 
the review protocol, including signs and symptoms of arthritis 
and commonly used composite measures, respective core set 
variables, physical function, patient- reported outcomes and 
measures of structural damage.
Sixteen research questions were defined according to the 
Patient population, Intervention, Control, Outcome (PICO) 
principle with the help of the steering committee. All typical RA 
study populations were included, methotrexate (MTX)- naïve 
or generally DMARD- naïve patients, csDMARD insufficient 
responders (IR), bDMARD- IR or tsDMARD- IR. Adequately 
defined control groups receiving either placebo or active treat-
ment were mandatory for inclusion in this analysis. These 
involved the efficacy of bDMARDs with or without csDMARD 
combination, head- to- head comparisons of bDMARDs and 
switching between different bDMARDs, tapering and stopping 
bDMARDs, as well as the efficacy of tsDMARDs and the respec-
tive head- to- head comparison to bDMARDs. Other research 
questions involved biosimilars, switching between bsDMARDs 
and respective boDMARD, the efficacy of csDMARDs and the 
efficacy of GC (in combination with csDMARDs). All interven-
tions of interest are shown in online supplementary table S1.7. 
A detailed description of the PICOs is shown in online supple-
mentary table S1.8.
Risk of bias (RoB) in individual studies was assessed at study 
level using the Cochrane Collaborations Risk of Bias tool for 
randomised controlled trials (RCTs). The assessment was done 
independently by two investigators (AK and AS). Differing 
assessments were discussed until consensus was reached.
Due to the heterogeneity of the available studies, no meta- 
analysis was performed, and results will be reported narra-
tively. Descriptive forest plots were created using RevMan V.5.3 
(Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014).
ResulTs
The study selection process involved 15 037 references. After 
deduplication, 7876 remained for title and abstract screening, of 
which 234 were selected for full article review and 136 articles 
finally included. A detailed flow chart is depicted in figure 1. 
Details of all studies included are shown in online supplementary 
table S2.1.
RoB was considered as low for most RCTs included. RCTs were 
rated as having an unclear RoB most commonly due to insuffi-
cient reporting of random sequence generation and/or allocation 
concealment. Due to their unblinded nature, open- label studies 
were considered as having a high RoB. Trials reported in confer-
ence abstracts were not assessed regarding RoB due to limited 
information. Results of the RoB assessment are shown in online 
supplementary table S2.2.
Characteristics of each trial for which data were extracted 
(study size, PICOs), baseline characteristics (online supplemen-
tary table S2.3–S2.12), results of studies and summary data for 
each intervention group (online supplementary table S3.1–S3.13) 
as well as the respective citations (section 4 in the online supple-
mentary appendix) are shown in the supplement. A summary 
of included trials and therapies investigated is shown in table 1.
efficacy of csdMARds (or combination of csdMARds) versus 
other csdMARds
Five trials (all with unclear or high RoB) investigated the efficacy 
of csDMARDs alone or in combination versus other csDMARDs 
(see table 1). Baseline characteristics and detailed results are 
shown in online supplementary table S2.12 and online supple-
mentary table S3.13, respectively.
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Figure 1 PRISMA flow chart describing the study selection process. DMARDs, disease- modifying antirheumatic drugs; PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses; SLR, systematic literature research.
The open- label CareRA trial (high RoB) stratified very early, 
csDMARD naive patients based on their risk factors (presence 
of erosions, disease activity, rheumatoid factor and anticitrul-
linated protein antibodies) into high and low risk.10 High- risk 
patients were randomised to three different csDMARD regimens 
(Combination therapy for early Rheumatoid Arthritis (COBRA) 
classic: methotrexate (MTX)+sulfasalazine (SSZ) + prednisone 
60 mg step- down vs COBRA Slim: MTX+prednisone 30 mg 
step- down vs COBRA Avant Garde: MTX+leflunomide (LEF) 
+ prednisone 60 mg step- down). Low- risk patients were either 
randomised to MTX tight- step up or COBRA Slim). The treat-
ment arms investigated in high- risk patients showed comparable 
efficacy in achieving the primary endpoint (Disease Activity 
Score of 28 joints (DAS28)- C reactive protein (CRP) <2.6) at 
week 52 for COBRA Classic (64.3%, 63/98).
COBRA Slim (60.2%, 59/98) and COBRA Avant Garde 
(62.4%, 58/93, p=0.840). In low- risk patients, COBRA- Slim 
and MTX- tight step up also showed comparable efficacy at week 
52 (67.4%, 29/43 vs 57.4%, 27/47, p=0.329). However, the 
area under the curves for mean DAS28- CRP change from base-
line as well as time- to- remission were favouring MTX plus pred-
nisone combination therapy. Radiographic damage was minimal 
and comparable across all treatment arms. Sustained and compa-
rable efficacy was shown after 2 years of treatment in high- risk 
patients.11
Investigation of LEF plus SSZ plus hydroxychloroquine (HCQ) 
triple therapy compared with MTX+SSZ+ HCQ triple therapy 
or LEF alone in a 48- week double- blind RCT was terminated 
early due to gastrointestinal complications in the LEF +SSZ+ 
HCQ arm. Conventional triple therapy (MTX+SSZ+ HCQ) 
was superior to LEF +SSZ+ HCQ and LEF alone (ACR20: 87% 
vs 46%, p<0.01, 87% vs 36%, p<0.001, respectively), with no 
apparent efficacy benefit of the LEF triple therapy compared 
with LEF alone at week 48 (ACR20: 46% vs 36%, p>0.05).12
efficacy of bdMARds, alone or in combination with 
csdMARds, in csdMARd and bdMARd-IR patients with 
(established) RA
Trials comparing bDMARDs to placebo with or without 
csDMARD background therapy (21 articles/abstracts, 7 with 
low RoB) showed effective reduction of signs and symptoms 
for several different modes of action (see table 1), including 
molecules targeting B- cells (SBI-087, BCD-020),13 14 inter-
feron-6 (IL-6) receptor (sarilumab),15 16 IL-6 cytokine (siru-
kumab, olokizumab, vobarilizumab),17–22 GM- CSF receptor 
(mavrilimumab) and GM- CSF cytokine (otilimab).23–25 IL-12/23 
inhibition (ustekinumab) and IL23i (guselkumab) did not show 
significant differences from placebo. Molecules targeting IL- 17A 
(secukinumab, CNTO6785),26–28 and CD4 (tregalizumab) 
showed no or only minor efficacy compared with placebo 
(and lower efficacy compared with abatacept (ABA) as active 
comparator) in different patient populations.29 Primary efficacy 
outcomes are summarised in table 2, baseline characteristics are 
shown in online supplementary table S2.3 and secondary effi-
cacy outcomes in online supplementary table S3.1.
Trials comparing bsdMARds to bodMARds
Twenty- four non- inferiority trials (12 with low RoB) inves-
tigated the bioequivalence of bsDMARDs to their respective 
boDMARDs. All showed conclusive comparable results, irre-
spective of the compound (adalimumab (ADA), etanercept, 
infliximab and rituximab; for bsDMARD studied see table 1, 
online supplementary table S2.10 and online supplementary 
table S3.11).30–55
Switching between biosimilars and bio- originators revealed 
no changes in efficacy in trials of one ADA (SB5, low RoB),56 
three etanercept (two with low RoB: GP2015, LBEC0101; 
CHS-0214: conference abstract—RoB not assessed),32 57–59 and 
two infliximab biosimilars (SB2, CT- P13, both low RoB).60 61 
Detailed characteristics and results of the studies are shown in 
online supplementary tables S2.11 and S3.11.
Head-to-head studies (bdMARds)
Seven bDMARD head- to- head studies were included (six with 
low RoB; one high RoB). Efficacy results are summarised in 
table 3 (baseline characteristics and detailed efficacy outcomes 
are shown in online supplementary tables S2.3 and S3.2.).
The Optimal Management of patients with rheumatoid 
arthritis who Require Biologic Therapy (ORBIT) trial (high 
RoB), an open- label non- inferiority RCT comparing B- Cell 
depletion (rituximab) to tumour necrosis factor inhibitor (TNFi) 
therapy in csDMARD- IR and bDMARD- naïve patients, found 
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Table 1 Interventions and therapeutic compounds of trials included for review
Intervention no of articles/ abstracts* Therapeutic compound Target
csdMARds, csdMARd combination, 
Glucocorticoids versus other csdMARds 
or placebo (10–12 130 131)
5 Tacrolimus +methotrexate (MTX) versus 
leflunomide+MTX
FKBP12; dihydrofolate reductase 
+purine metabolism; dihydroorotate 
dehydrogenaseMTX+sulfasalazine + glucocorticoids versus 
MTX +glucocorticoids versus MTX +Leflunomide 
+Glucocorticoids
MTX versus MTX+glucocorticoids
MTX+sulfasalazine + Hydroxychloroquine versus 
leflunomide +sulfasalazine + hydroxychloroquine 
versus leflunomide monotherapy














Mavrilimumab GM- CSF receptor
Ustekinumab IL-12/23
Guselkumab IL-23
bdMARds versus other bdMARds (4 62–66 
137 138)
8 Rituximab versus etanercept/adalimumab CD-20 versus TNF
ABT-122 versus adalimumab TNF/IL- 17A versus TNF
Certolizumab pegol versus adalimumab TNF
Sirukumab versus adalimumab IL-6 versus TNF
Sarilumab versus adalimumab IL-6 receptor versus TNF
Secukinumab versus abatacept IL-17 versus CD-80/CD-86
Mavrilimumab versus golimumab GM- CSF versus TNF
bdMARd induction versus csdMARd 
induction in early disease (69–72 139)
5 Certolizumab pegol versus MTX TNF
Abatacept versus MTX CD-80/CD-86
Infliximab versus MTX TNF
Tocilizumab versus MTX IL-6 receptor
switching between bdMARds (4 67 68) 3 Certolizumab pegol versus adalimumab TNF
Abatacept; rituximab; tocilizumab versus adalimumab; 
certolizumab; infliximab; golimumab; etanercept
CD-80/CD-86; CD-20; IL-6 receptor 
versus TNF
Sarilumab IL-6 receptor
Tapering of bdMARds/tsdMARds or 
csdMARds (107–124 126–128 140–145)
25 Abatacept CD-80/CD-86
Tocilizumab IL-6 receptor
Adalimumab; certolizumab pegol; etanercept; 
infliximab;
TNF
csDMARDs   
Glucocorticoids   
strategic studies (6 146) 2     
tsdMARds±csdMARds versus placebo 
(73–100 125 147–152)









5 Baricitinib versus adalimumab JAK 1/2 versus TNF
Tofacitinib versus adalimumab JAK 1/3 versus TNF
Upadacitinib versus adalimumab JAK 1 versus TNF
Continued
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Intervention no of articles/ abstracts* Therapeutic compound Target
bsdMARds versus bodMARds (30–34 36–55) 24 Adalimumab: ABP 501, AdaliRel, BI 695501, CinnoRA, 
FKB327, GP2017, PF-06410293, SB5, ZRC 3197
TNF
Etanercept: CHS-0214, GP2015, HD203, LBEC0101 TNF
Infliximab: BCD-055, CT- P13, NI-071, PF-06438179/
GP1111, SB2
TNF
Rituximab: BCD-020, CT- P10, DRL- RI, GP2013 CD-20
switching between bsdMARds and 
bodMARds (32 35 56–61 153)
6 Adalimumab: SB5 TNF
Etanercept: GP2015, CHS-0214, LBEC0101 TNF
Infliximab: SB2, CT- P13 TNF
*Studies answering multiple research questions account for mismatch between included articles/abstracts and numbers in this table. References of manuscripts published after 
the SLRs data cut, with the respective conference abstracts included before, are shown, but were not counted.
bDMARD, biological disease- modifying antirheumatic drug; boDMARD, biooriginator disease- modifying antirheumatic drug; bsDMARD, biosimilar disease- modifying 
antirheumatic drug; CD, cluster of differentiation; csDMARD, conventional synthetic disease- modifying antirheumatic drug; GM- CSF, granulocyte- macrophage colony- stimulating 
factor; IL, interleukin; JAK, Janus kinase; SYK, spleen tyrosine kinase; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease- modifying antirheumatic drug.
Table 1 Continued
that RTX is non- inferior to TNFi over 52 weeks regarding clin-
ical efficacy.62
Sarilumab monotherapy showed clinical and functional supe-
riority compared with ADA monotherapy in patients who were 
intolerant or inadequately responding to MTX.63
Mavrilimumab (targeting GM- CSFR) was compared with 
golimumab in a 24- week phase 2b trial of csDMARD and/or 
TNFi- IR patients and had similar efficacy.64
ABT-122, a bispecific dual variable domain immunoglobulin 
targeting TNF and IL- 17A, exhibited similar efficacy rates in the 
120 mg arm as ADA in MTX- IR patients over 12 weeks.65
The SIRROUND- H study investigated superiority of siru-
kumab (IL- 6i) monotherapy over ADA monotherapy in MTX- 
IR, bDMARD naive patients. The study failed to meet one 
of its coprimary endpoints with no significant differences in 
ACR50% response rates at week 24; the other primary endpoint 
(DAS28- ESR mean change from baseline at week 24) was met.66
The EXXELERATE study did not show superiority of certoli-
zumab pegol compared with ADA and therefore failed to meet 
its primary endpoint, showing similar ACR20% response rates 
at week 12.4
switching between different bdMARds
Three trials on switching between different bDMARDs were 
included (see online supplementary table S2.4 and online supple-
mentary table S3.3 for details).
EXXELERATE also studied the efficacy of single- blinded 
switching to a second TNFi (without washout) in patients with 
primary non- response to either certolizumab pegol or ADA 
(unclear RoB). Twelve weeks after switching 58% (ADA to 
certolizumab pegol) and 62% (certolizumab pegol to ADA) of 
patients achieved DAS28- ESR≤3.2 or a DAS28- ESR reduction 
of 1.2 or more.4
An exploratory analysis of the EXTEND trial, an open- label 
extension study of the ASCERTAIN trial, investigated patients 
switched from tocilizumab (TCZ) to sarilumab (conference 
abstract). After 12 and 24 weeks about one- third of patients 
non- responders to TCZ achieved clinical response (Clinical 
Disease Activity Index (CDAI) ≤10; ACR70) after switching to 
sarilumab.67
The open- label ROC trial (high RoB) investigated patients 
who failed one TNFi therapy, comparing non- TNFi therapies 
(ABA, RTX, TCZ) to a second TNFi drug. The primary efficacy 
endpoint, superiority in EULAR good or moderate response at 
week 24, was met with higher responses in the non- TNFi group 
(101/146, 69%) compared with 52% in the second TNFi group 
(OR 2.12; 95% CI 1.31 to 3.46; p=0.003).68 bDMARD thera-
pies in early RA patients.
Five reports on induction therapy with bDMARDs in early 
disease were included (two with low RoB), baseline characteris-
tics are shown in online supplementary table S2.5 and results in 
online supplementary table S3.4.
In DMARD naïve patients with poor prognostic factors, CZP 
in combination with dose optimised MTX (C- EARLY) was 
shown to be superior to placebo +MTX, with 28.9% of patients 
achieving sustained DAS28 <2.6 at week 40 and week 52 in the 
combination arm compared with 15% of patients in the MTX 
arm.69
In the AVERT-2 study, ABA+MTX did not show superiority 
to placebo +MTX regarding SDAI remission (≤3.3) at week 24 
(21.3% ABA+MTX vs 16% placebo +MTX), the primary effi-
cacy endpoint.70
DINORA compared infliximab +MTX treatment to MTX 
or placebo treatment only. INF+MTX showed superiority 
to placebo only, but not to MTX monotherapy, in achieving 
sustained remission (no swollen joints, ≤2 tender joints and an 
acute phase within the normal range) after 1 year (32% vs 14% 
vs 0% for INF+MTX, MTX and placebo, respectively).71
TCZ monotherapy as well as combination therapy of TCZ 
with MTX was clinically superior to MTX therapy in early RA 
patients. Inhibition of radiographic damage was found to be 
significantly greater with 8 mg/kg TCZ intravenous +MTX 
than in the MTX monotherapy arm modified total Sharp score 
(ΔmTSS 0.08 vs 1.14). TCZ 8 mg/kg intravenous monotherapy 
showed less radiographic progression than MTX monotherapy 
(ΔmTSS 0.26 vs 1.14, p value not reported).72
efficacy of tsdMARds (JAKi)
In total, 32 articles/abstracts on tsDMARDs were included 
(see table 1); 16 trials were regarded as having low RoB. Base-
line characteristics and efficacy outcomes are shown in online 
supplementary tables S2.8 and S3.9, respectively.
Decernotinib (JAK- 3i) and peficitinib (non- selective JAKi) 
were effective as monotherapy and in combination with 
csDMARDs or MTX in various populations.73–82
Filgotinib (JAK-1 selective JAKi) was effective in reducing 
signs and symptoms of RA as well as improving physical function 
and patients quality of life in two phase II studies investigating 
MTX- IR patients in combination with MTX (DARWIN 1) and 
as monotherapy (DARWIN 2).83
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Table 2 Primary efficacy outcomes of trials comparing biological DMARDs with or without background csDMARD therapy to placebo
study Risk of bias Treatment n
Time point 
(weeks) Primary endpoint Outcome P value
Damjanov 201613 High Pbo/Pbo/Pbo+MTX 40 16 ACR 20 (%) NR Reference
SBI-087/Pbo/Pbo+MTX 43 NR NS
SBI-087/SBI-087/Pbo+MTX 42 NR NS
SBI-087/Pbo/SBI-087+MTX 43 NR NS
SBI-087/SBI-087/SBI-087+MTX 41 NR 0.046
Mazurov 201814 Abstract Placebo +MTX 52 24 ACR 20 (%) 29 Reference
BCD-020 600 mg+MTX 107 66 <0.001
Fleischmann 2017 
(TARGET)15
Low Placebo +csDMARDs 181 12/24 ACR 20 (%) / ΔHAQ- DI 34/−0.3 Reference
SLM 150 mg Q2W+csDMARDs 181 56/−0.5 <0.001
SLM 200 mg Q2W+csDMARDs 184 61/−0.6 <0.001
Tanaka 2018b 
(KAKEHASI)16
Abstract Placebo +MTX 82 24 ACR 20 (%) 15 Reference
SLM 150 mg Q2W+MTX 81 68 <0.001
SLM 200 mg Q2W+MTX 80 58 <0.001
Aletaha 2017 
(SIRROUND- T)17 18
Low Placebo±csDMARDs 294 16 ACR 20 (%) 24 Reference
SKM 50 mg Q4W±csDMARDs 292 40 <0.001
SKM 100 mg Q2W±csDMARDs 292 45 <0.001
Takeuchi 2017 
(SIRROUND- D)19
Unclear Placebo +csDMARD 556 16/52 ACR 20 (%)/ΔmTSS 26/1.96 Reference
SKM 50 mg Q4W+csDMARD 557 55/0.35 <0.001
SKM 100 mg Q2W+csDMARD 557 54/0.3 <0.001
Takeuchi 2016 
(RA0083)20
Low Placebo +MTX 29 12 ΔDAS28- CRP −0.64 Reference
OKZ 60 mg Q4W+MTX 32 −2.18 <0.001
OKZ 120 mg Q4W+MTX 32 −2.45 <0.001
OKZ 240 mg Q4W+MTX 36 −2.68 <0.001
Dorner 201721 Abstract (Open- Label) TCZ 162 mg QW 60 12 ACR 20 (%), no formal 
comparison
78 NR
VBM 150 mg Q4W 62 73
VBM 150 mg Q2W 62 77
VBM 225 mg Q2W 63 81
Weinblatt 201722 Abstract Placebo +MTX 69 12 ACR 20 (%) 62 Reference
VBM 75 mg Q4W+MTX 69 75 NS
VBM 150 mg Q4W+MTX 70 81 NS
VBM 150 mg Q2W 68 78 NS
VBM 225 mg Q2W 69 72 NS
Burmester 2017b 
(EARTH EXPLORER 1)23
Low Placebo +MTX 81 12/24 ACR 20 (%)/ΔDAS28- 
CRP
25/−0.68 Reference
MVM 150 mg Q2W+MTX 79 51/−1.9 <0.001
MVM 100 mg Q2W+MTX 85 61/−1.64 <0.001
MVM 30 mg Q2W+MTX 81 73/−1.37 <0.001
Buckley ACR 201824 25 Abstract Placebo +MTX 37 12 DAS28- CRP <2.6 (%) 3 Reference
OTM 22.5 mg +MTX 37 5 0.547
OTM 45 mg+MTX 37 16 0.077
OTM 90 mg+MTX 37 19 0.053
OTM 135 mg+MTX 37 14 0.122
OTM 180 mg+MTX 37 14 0.134
Tahir 2017 (REASSURE)26 Unclear Placebo±MTX 214 24 ACR 20 (%) 19.6 Reference
SEC 3×10 mg/kg i.v. Q2W/150 mg s.c. 
Q4W±MTX
213 35 <0.001
SEC 3×10 mg/kg i.v. Q2W/75 mg s.c. 
Q4W±MTX
210 35 <0.001
Mease 201827 Unclear Placebo +MTX 51 16 ACR 20 (%) 41 Reference
CNTO6785 15 mg Q4W+MTX 52 52 NS
CNTO6785 50 mg Q4W+MTX 51 47 NS
CNTO6785 100 mg Q4W+MTX 51 37 NS
CNTO6785 200 mg Q4W+MTX 52 40 NS
Dokoupilova 2018 
(REASSURE2)28
Unclear Placebo +csDMARDs 81 24 ACR 20 (%) 27 Reference
SEC 150 mg+csDMARDs 81 38 0.157
SEC 75 mg+csDMARDs 80 38 0.200
Continued
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study Risk of bias Treatment n
Time point 
(weeks) Primary endpoint Outcome P value
van Vollenhoven 201829 Low Placebo +MTX 79 12 ACR 20 (%) 35 Reference
TLM 25 mg+MTX 80 42 0.395
TLM 100 mg+MTX 78 47 0.165
TLM 200 mg+MTX 76 44 0.274
Bi 2018 (RAPID- C)132 High Placebo +MTX 113 24 ACR 20 (%) 24 Reference
CZP +MTX 316 55 <0.001
Smolen 2017a133 Low Placebo +MTX 55 28 ACR 20 (%) 40 Reference
UKM 90 mg Q8W+MTX 55 53 0.877
UKM 90 mg Q12W+MTX 55 55
GKM 50 mg Q8W+MTX 55 38 0.101
GKM 200 mg Q8W+MTX 54 44
Detailed results of risk of bias analyses are shown in online supplementary table S2.2 in the supplementary appendix.
Δ, change from baseline; ACR, American College of Rheumatology response criteria; csDMARD, conventional synthetic disease- modifying antirheumatic drugs; CZP, certolizumab 
pegol; DAS28- CRP, Disease Activity Score of 28 joints with C- reactive protein; GKM, guselkumab; HAQ- DI, Health Assessment Questionnaire Disability Index; i.v., intravenous; 
mTSS, modified total Sharp score; MTX, methotrexate; MVM, mavrilimumab; NR, not reported; NS, not significant; OKZ, olokizumab; OTM, Otilimab; Pbo, placebo; s.c., 
subcutaneous; SEC, secukinumab; SKM, sirukumab; SLM, sarilumab; TCZ, tocilizumab; TLM, tregalizumab; UKM, ustekinumab; VBM, vobarilizumab.
Table 2 Continued
GS-9876, an oral spleen tyrosine kinase inhibitor did not 
show clinical efficacy compared with placebo.84
Baricitinib (BARI) (JAK-1/2i) showed efficacy compared with 
placebo in csDMARD- IR (RA- BUILD) patients,85 86 MTX- IR 
patients,87 88 and in early RA as monotherapy or in combination 
with MTX.89 90
Upadacitinib proved to be efficacious versus placebo in phase 
3 trials of various RA populations, MTX- naive,91 csDMARD/
MTX- IR,92–98 bDMARD- IR (SELECT- BEYOND)99 100 and 
tsDMARD versus bDMARD head- to- head trials.
Five reports on three different head- to- head trials (three with 
low RoB) comparing tsDMARDs to ADA were included. Base-
line characteristics are shown in online supplementary table S2.9 
and detailed efficacy results in online supplementary table S3.10.
In RA- BEAM, BARI 4 mg+MTX was shown to be superior 
to ADA 40 mg Q2W+MTX clinically (ACR20 at week 12: 70% 
vs 61%, p=0.014; ΔDAS28- CRP at week 12: −2.24 vs −1.95, 
p<0.001) and functionally (ΔHAQ at week 12: −0.66 vs −0.56, 
p≤0.01). Regarding structural progression, ADA and BARI were 
superior compared with placebo (change from baseline in mTSS 
at week 24: BARI: 0.41 vs ADA: 0.33 vs placebo: 0.9, p vs 
placebo <0.001).101 102 Regarding core set variables, the differ-
ences related to patient reported outcomes and CRP, but not to 
swollen joint counts (SJCs).
ORAL strategy investigated the non- inferiority of tofacitinib 
5 mg two times per day with or without MTX compared with 
ADA 40 mg Q2W+MTX. Non- inferiority was demonstrated 
for tofacitinib +MTX versus ADA +MTX (ACR50 at week 24: 
46% vs 44%, difference: 2%; 98.34% CI −6% to 11%), but 
not for tofacitinib monotherapy versus ADA +MTX (ACR50 
at week 24: 38% vs 44%; −6% (−14%–3%)) or versus tofaci-
tinib +MTX (ACR 50 at week 24: 38% vs 46%; −8% (−16%–
1%)).103 104
Upadacitinib+MTX was shown to be superior to ADA +MTX 
in SELECT- COMPARE in both coprimary endpoints (ACR20 at 
week 12: 70.5% vs 63%, p<0.05; DAS28- CRP<2.6 at week 
12: 28.7% vs 18%, p<0.001), with radiographic superiority of 
upadacitinib +MTX vs placebo +MTX (ΔmTSS at week 26: 
0.24 vs 0.92, p<0.001) and numerically similar results between 
upadacitinib +MTX and ADA +MTX (ΔmTSS at week 26: 
0.24 vs 0.10).105 106 Also in this study, the differences related to 
patient- reported outcomes and CRP, but not to SJCs.
Key outcomes are summarised in table 4. Figure 2 shows 
descriptive forest plots using ACR 20/50 and 70 response rates. 
Figure 3 summarises outcomes of trials investigating the efficacy 
of bDMARDs and tsDMARDs (based on their mode of action) 
compared with placebo.
strategy trials
IMAGINE- RA, a non- blinded strategic trial (high RoB) which 
enrolled patients with stable, controlled disease activity 
(DAS28- CRP ≤3.2 and no swollen joints), compared an MRI 
guided with a purely clinical treat- to- target strategy. The trial did 
not meet its coprimary endpoints at month 24, as no differences 
in DAS28- CRP<2.6 rates (85% vs 88%, respectively) or differ-
ences in the proportion of patients who had no radiographic 
progression (66% vs 62%) were observed. However, in the MRI- 
T2T group, more patients needed treatment escalation (73% vs 
17%) and initiation of bDMARD therapy (46% vs 2%) accom-
panied by higher costs and three times more serious adverse 
events.6
Tapering and stopping therapy
In total 25 studies (three with low RoB) investigated tapering 
and/or stopping csDMARD, bDMARD or tsDMARD therapy. 
Primary results are shown in table 5, baseline characteristics 
are shown in online supplementary table S2.7 and secondary 
outcomes are shown in online supplementary tables S3.6, S3.7 
and S3.8
Tapering and stopping csdMARds or GCs
MUSICA, a double- blind, non- inferiority RCT (low RoB) 
investigated randomised MTX dosage reduction to 7.5 mg/
week compared with continuation of 20 mg/week in MTX- IR 
patients with open- label ADA initiation. The mean DAS28- CRP 
was statistically lower in the standard- dose group (3.75 vs 4.12, 
p=0.014) and non- inferiority of high versus low MTX dosage 
was therefore not shown (ΔDAS28- CRP 0.37 (95% CI 0.07 to 
0.66) at week 24; NI- margin: 15%=0.56).107 Thus, a mandatory 
dose reduction from 20 to 7.5 mg MTX weekly seems too low 
for combination therapy with a TNFi.
A Canadian open- label RCT (high RoB) reported no differences 






















Table 3 Head- to- head studies comparing bDMARDs to other bDMARDs
Population study
Risk of 











MTX- IR Burmester 2017 
(MONARCH)63 137
Low ADA 40 mg Q2W 185 ΔDAS28- ESR at week 24 <0.001 58 30 12 7 3 −0.43
SLM 200 mg Q2W 184 72 46 23 27 7 −0.61
Smolen 2016 
(EXXELERATE)4
Low ADA 40 mg Q2W+MTX 454 ACR 20 (%) at week 12 0.532 71 22
CZP 400/200 mg Q2W+MTX 454 69 25
Taylor 2018 
(SIRROUND- H)66
Low ADA 40 mg Q2W 186 ACR 50 (%) + ΔDAS28- ESR at 
week 24
Reference 57 32 13 8 −0.52
SKM 50 mg Q4W 186 0.306/0.013 54 27 12 13 −0.51
SKM 100 mg Q2W 187 0.464/ <0.001 59 35 16 20 −0.53
Genovese 2018b65 Low ADA 40 mg Q2W+MTX 56 ACR 20 (%) at week 12 Reference 68 48 21 30 7 −0.6
ABT-122 60 mg Q2W+MTX 55 0.863 62 35 22 22 7 −0.6
ABT-122 120 mg Q2W+MTX 56 0.414 75 46 18 38 11 −0.6
ABT-122 120 mg QW +MTX 55 0.196 80 47 36 42 11 −0.9
csdMARd- IR Porter 2016 (ORBIT)62 High Anti- CD20 (RTX) 140 ΔDAS28- ESR (non- inferiority) at 
week 52
0.24 66 49 23 23 −0.49
TNFi (ETA/ADA) 134 71 45 26 21 −0.38
TnF- IR Blanco 2017 (NURTURE 
1)138
Low Placebo +csDMARD 138 ACR 20 (%) at week 24 Reference 18 9 5 −0.3
ABA 500/750/1000mg+csDMARD 138 <0.05 43 28 12 −0.6
SEC 10 mg/kg i.v. +150 mg s.c. 
Q4W+csDMARD
137 0.031 31 17 10 −0.4
SEC 10 mg/kg i.v. +75 mg s.c. 
Q4W+csDMARD
138 0.092 28 12 5 −0.3
Mixed cs/bdMARd- 
IR
Weinblatt 2018 (EARTH 
EXPLORER 2)*64
Low GLM 50 mg Q4W 68 ACR 20/50/70%, DAS28- CRP <2.6, 
ΔHAQ>0.22 at week 24
0.666/0.293/0.156/0.108/0.208 66 43 26 29 18 −0.64
MVM 100 mg Q2W+MTX 70 62 35 16 17 6 −0.44
Results of secondary efficacy outcomes are shown at the time point of the primary endpoint.
*Study not powered to formally compare the treatments. Detailed results of risk of bias analyses are shown in online supplementary table S2.2 in the supplementary appendix.
Δ, change from baseline; ABA, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; bDMARDs, biological disease- modifying antirheumatic drugs; CDAI, clinical disease activity index; CRP, C- reactive protein; csDMARDs, conventional synthetic 
disease- modifying antirheumatic drugs; CZP, certolizumab pegol; DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; ETA, etanercept; GLM, golimumab; HAQ, Health Assessment Questionnaire; i.v., intravenous; MTX, methotrexate; MVM, 
mavrilimumab; RTX, rituximab; SEC, secukinumab; SKM, sirukumab; SLM, sarilumab; TNFi, TNF inhibitor; TNF- IR, tumour necrosis factor- insufficient responder.
























































































































































































































































































































































































































































































































































































































































































































































































































































































plus csDMARD had been randomised to continue combination 
therapy or discontinue csDMARDs (−2.1 vs −2.1).108–110
The SEMIRA trial (conference abstract) investigated patients 
treated with TCZ ±csDMARD therapy who also had stable GC 
therapy of 5 mg/day, comparing blinded tapering of GCs with 
continuation of GCs. A significant increase of disease activity 
(ΔDAS28- ESR) was seen in the discontinuation group compared 
with continuation (0.613, 95% CI 0.346 to 0.879, p<0.001). 
Sixty- six per cent of patients discontinuing remaining in stable 
DAS28 ≤3.2 without experiencing disease flares, compared with 
77% (RR 0.833, 95% CI 0.714 to 0.972, p=0.021) in the stable 
GC group.111
Several trials (one low RoB, one unclear RoB, one high RoB) 
showed non- inferiority of MTX tapering versus continuation in 
patients receiving ongoing (long- term) TCZ therapy.112–114
A substudy of the CareRA study investigated randomised 
step- down from COBRA Avant- Garde (MTX+LEF + initial 
prednisone 30 mg step- down) to either MTX (15 mg/week) or 
LEF (20 mg/day) monotherapy if they achieved an DAS28- CRP 
≤3.2 after treatment induction during period of 40–52 weeks 
of therapy. After 65 weeks, significantly more patients achieved 
DAS28- CRP <2.6, CDAI ≤10 or SDAI ≤11 in the MTX arm 
(30/32, 93.8%; 32/32, 100%; 32/32, 100% respectively) than in 
the LEF arm (19/26, 73.1%, p=0.031; 21/26, 80.8%, p=0.009; 
22/26, 84.6%, p=0.021)115 116 bDMARD tapering.
The POET study, a large open- label RCT (high RoB) 
randomised patients in stable low disease activity for 6 months 
(DAS28- ESR ≤3.2 or based on rheumatologists’ impression) to 
either stop or continue their TNFi therapy, comparing propor-
tions of patients experiencing a disease flare (DAS28- ESR ≥3.2 
+ DAS28- ESR change from baseline >0.6) during 12 months. 
About 20% of patients could stop their TNFi therapy without 
experiencing a flare, but among those who continued TNFi 
therapy 50% did not experience a flare (TNFi stopping: 18.2% 
vs TNFi continuation: 51.2%, p<0.001; HR 3.50; 95% CI 2.60 
to 4.72).117 118
In C- OPERA, Japanese patients discontinued or continued 
certolizumab pegol after achieving DAS28- ESR ≤3.2 at week 
52. At week 104, 29.3% of patients who stopped certolizumab 
pegol could maintain SDAI remission, compared with 41.5% of 
patients continuing (p=0.026). Significantly more radiographic 
progression occurred in patients who stopped certolizumab until 
week 104 (ΔmTSS at week 104 0.66 vs 3.01, p=0.001).119
In C- EARLY, a trial investigating certolizumab +MTX in 
csDMARD naive patients with early RA, patients who achieved 
DAS28- ESR≤3.2 at year 1 were either continued on CZP every 
2 weeks, increased dosing interval of CZP (to every 4 weeks) 
or stopped CZP completely. Although the trial failed to meet 
its primary endpoint (% of patients in DAS28- ESR≤3.2 without 
flare at week 104), similar results for CZP Q2W versus interval 
prolongation to CZP every 4 weeks (48.8% vs 53.2%, p=0.112) 
were seen. Furthermore, 39.2% of patients could stop CZP 
completely and maintain DAS28- ESR ≤3.2 but the difference 
compared with continuation was significant (48.8% vs 39.2%, 
p=0.041).120
Further studies investigated the discontinuation of TCZ 
after combination therapy with MTX (SURPRISE study) and 
achieving DAS28- ESR <2.6: sustained DAS28- ESR <2.6 and 
DAS28- ESR ≤3.2 rates were more frequent in patients receiving 
concomitant MTX compared with TCZ monotherapy after 
104 weeks (24% vs 14%, p=0.005; 55% vs 27%, p=0.005).121 
Tapering TNFi dose by 33% in patients with DAS28- ESR ≤3.2 
for 3 months did not lead to increased flare rates (12% vs 16%, 
HR: 0.90, 95% CI 0.23 to 3.48, p=0.873), reducing the TNFi 
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Figure 2 Forest plots showing risk ratios of ACR 20, 50 and 70 responses in trials comparing JAK inhibitors+MTX to adalimumab +MTX in MTX- IR 
patients. 1, tofacitinib; 2, upadacitinib; 3, baricitinib. ACR, American College of Rheumatology; IR, insufficient responder; M- H, Mantel- Haenszel; MTX, 
methotrexate; JAK, Janus kinase.
Figure 3 Efficacy of different targets of biological and targeted 
synthetic disease- modifying drugs compared against placebo, shown 
across major clinical trial outcomes of randomised controlled trials 
published from 2016 to 2018. ACR, American College of Rheumatology 
response criteria; CD, cluster of differentiation; DMARD, disease- 
modifying antirheumatic drugs; EULAR, European League against 
Rheumatism; GM- CSF, colony- stimulating factor; HAQ, Health 
Assessment Questionnaire; IL, interleukin; JAK, Janus kinase; mTSS, 
modified total Sharp score; Syk, spleen tyrosine kinase; TNF, tumour 
necrosis factor.
dose by 66% resulted in not statistically significantly different 
flare rates (DAS28- ESR >3.2 and ΔDAS28- ESR ≥0.6) compared 
with treatment continuation (29% vs 16%, HR 2.52, 95% CI 
0.85 to 7.48, p=0.097).122
A novel tapering strategy, using a biomarker, matrix metal-
loproteinase (MMP-3), or combined SDAI +MMP-3- guided 
tapering of bDMARDs in patients achieving SDAI ≤3.3 and 
normalisation of MMP-3 showed non- inferiority at week 52 
as compared with just clinically guided maintenance of SDAI 
≤3.3.123 Open- label interval prolongation in patients with 
high ADA trough levels (defined as >8 µg/mL) did not lead to 
increased disease activity (using DAS28- ESR, CDAI or SDAI).124
Tapering of tsdMARds
The RA- BEYOND study randomised patients from four 
trials of BARI at 4 mg who had achieved stable CDAI ≤10 
to either continue BARI 4 mg or reduce dose to 2 mg. While 
more patients who continued full dose maintained CDAI low 
disease activity compared with those who reduced the dose 
(93% vs 83%, p<0.001 at 3 months; 87% vs 75%, p<0.001, 
at 6 months; 80% vs 67%, p<0.01 at 12 months for BARI 
4 mg continuation vs dose reduction to BARI 2 mg, respec-
tively), a majority of patients maintained their good disease 
state despite dose reduction. Further, in patients being in 
CDAI ≤2.8 at randomisation, fewer patients lost their disease 
activity state. Of those who flared after dose reduction, the 
majority (66.7%) regained their CDAI <10 state within 24 
weeks after dose increase to 4 mg. Thirteen of the 16 patients 
not regaining their CDAI <10 state after 24 weeks were able 
to do so at a subsequent time point.125
Combined bdMARds and csdMARds tapering and/or stopping
IMPROVED, a Dutch strategy trial (high RoB) aimed at drug 
free remission in patients with early RA and undifferentiated 
arthritis. After 5 years, 15%–20% (p=0.374) of patients could 
achieve drug- free remission.126
Dose reduction (by 50%) or stopping either csDMARDs, 
bDMARDs or both compared with dose continuation was inves-
tigated in a study of patients achieving stable DAS28- ESR <2.6 
for at least 6 months (high RoB). In the control group 6.5% of 
patients flared, while 42%–77% flared after dose reduction or 
stopping therapy completely.127
The TARA study compared csDMARD tapering with 
bDMARD tapering in patients who had long- standing combi-
nation therapy and found no significant differences in the flare 
(defined as DAS44 >2.4 and/or SJC >1) ratio between both 
groups (HR 0.91; 95% CI 0.68 to 1.22; p=0.55).128
dIsCussIOn
This SLR was performed to inform the task force for the 2019 
update of the EULAR recommendations for the management of 
RA on the efficacy of various DMARDs as presented in publica-
tions from 2016 to March 2019. These publications covered a 
total of 32 DMARDs.
The SLR confirmed the high efficacy of csDMARD plus GC 
combination therapy as well as the efficacy of TNFi, IL- 6Ri, ABA 
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Table 5 Primary outcomes of studies investigating csDMARD, bDMARD and tsDMARD tapering and stopping
study Primary outcome endpoint (week) Treatment arm n Result P value
csdMARd tapering
Kaeley 2016 (MUSICA)107 Mean DAS28- CRP 24 ADA 40 mg Q2W+7.5 mg MTX 154 4.12 0.014
ADA 40 mg Q2W+20 mg MTX 155 3.75
Keystone 2016 (CAMEO)144 ΔDAS28- ESR 24 ETN 50 mg QW; MTX discontinuation 98 0.5 0.815
ETN 50 mg QW +MTX continuation 107 0.04
Pope EULAR 2017/ACR 
2018/2019108–110
ΔDAS28- ESR 76 CZP +csDMARD continuation 37 −2.1 NR
CZP +csDMARD discontinuation 44 −2.1
Burmester ACR 2018 (SEMIRA)111 ΔDAS28- ESR 24 TCZ ±csDMARDs; GC tapering 131 0.538 <0.001
TCZ ±csDMARDs; GC continuation 128 −0.075
Pablos 2018 (JUST- ACT)112 ΔDAS28- ESR week 16 week 28 28 TCZ 8 mg/kg+MTX 82 0.007 95% CI −0.40 to 0.27
TCZ 8 mg/kg+PLC 82 0.073
Kremer 2018 (COMP- ACT)113 ΔDAS28- ESR week 24 week 40 40 TCZ 162 mg s.c. +PLC 147 0.46 95% CI 0.045 to 0.592
TCZ 162 mg s.c. +MTX 147 0.14
Edwards 2018 (ACT- TAPER)114 Pat. Maintaining EULAR good/moderate response from 
week 24–60
60 TCZ 8 mg/kg Q4W+PBO 136 77% 0.036
TCZ 8 mg/kg Q4W+MTX 136 65%
Stouten 2018 (CareRA)115 116 DAS28- CRP <2.6 65 MTX +LEF->MTX 15 mg/week 32 94% 0.031
MTX+LEF->LEF 20 mg/day 26 73%
bdMARd tapering
Oba 2017/Tanaka ACR 2018 
(RRRR)140 141
1- year sustained discontinuation rate of INF 106 INF 3 mg/8 mg/10 mg/kg Q8W based on TNF 
levels
170 24% 0.631
INF standard 3 mg/kg Q8W 167 21%
Chatzidionysiou 2016 (ADMIRE)142 DAS28 <2.6 at week 28 28 ADA +MTX continuation 16 94% 0.001
ADA discontinuation; MTX monotherapy 16 33%
Ghiti Moghadam 2016/2018 
(POET)117 118
% of pat. DAS28 ≥3.2 + ΔDAS28 >0.6 for 1 year 52 Stopping TNFi 531 51% <0.001
Continuation of TNFi 286 18%
Atsumi 2017 (C- OPERA)119 ΔmTSS 104 CZP +MTX continuation 108 0.66 0.001
Stopping CZP; MTX+PLC 71 3.01
Kaneko 2018 (SURPRISE)121 TCZ free rate 104 stopping TCZ; MTX monotherapy 49 67% 0.001
stopping TCZ; No DMARD 53 29%
Weinblatt 2017 (C- EARLY)120 DAS28- ESR ≤3.2 without flares during week 52–104 104 CZP 200 mg Q2W+MTX (standard) 84 49% Reference
CZP 200 mg Q4W+MTX (reduced frequency) 126 53% 0.112
Placebo +MTX (CZP stopped) 79 39% 0.041
Ibrahim 2017 (OPTIRRA)122 Flare rate (ΔDAS28 ≥0.6 + DAS28 >3.2 + ΔSJC OR 
ΔDAS28 >1.2 + DAS28 >3.2)
24 TNFi 33% tapering; csDMARD 26 12% 0.873
TNFi 66% tapering; csDMARD 21 29% 0.097
Control; csDMARD continuation 50 16% Reference
Bouman 2017 (DRESS)145 Incidence of major flare (ΔDAS28- CRP >1.2 or ΔDAS28- 
CRP >0.6+DAS28- CRP ≥3.2 for >12 weeks)
144 TNFi dose reduction extension 115 17% 3%, 95% CI -10% 
to 15%
Usual care extension 57 14%
l’Ami 2018124 ∆DAS28- ESR 28 ADA 40 mg Q3W±MTX 27 −0.14 0.01
ADA 40 mg Q2W±MTX 27 0.3
tsdMARd tapering
Takeuchi 2019 (RA- BEYOND)125 CDAI ≤10 12 Continued BARI 4 mg±csDMARD 281 93% <0.001
BARI Step- down 2 mg±csDMARD 278 83%
Δ, change from baseline; ACR, American College of Rheumatology; ADA, adalimumab; BARI, baricitinib; bDMARD, biological disease- modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; CRP, C- reactive protein; csDMARDs, conventional synthetic disease- modifying 
antirheumatic drugs; CZP, certolizumab pegol; DAS28, Disease Activity Score of 28 joints; ESR, erythrocyte sedimentation rate; ETN, etanercept; EULAR, European League against Rheumatism; GC, glucocorticoid; INF, infliximab; LEF, leflunomide; mTSS, modified total Sharp Score; MTX, 
methotrexate; MTX, methotrexate; PLC, placebo; SJC, swollen joint count; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor; tsDMARD, targeted synthetic DMARD.
and rituximab as well as bsDMARDs in csDMARD (including 
MTX) IR patients. With respect to bsDMARDs, switch (including 
multiple switch) studies between bs and boDMARDs confirmed 
long- term safety and efficacy of biosimilars. Like bDMARDs, 
JAKi are efficacious in patients with RA. Several trials compared 
one bDMARD class (usually TNFi agents) with bDMARDs of 
other classes revealing similarity of response. Likewise, head- to- 
head trials between JAKi and anti- TNF did not reveal clinically 
important differences regarding efficacy.
In patients who failed a TNFi or other bDMARDs, 
tsDMARDs and also bDMARDs of the same or other classes 
revealed generally similar clinical efficacy4 99 100 or relatively 
small differences.68 Of interest (and part of the previous 
research agenda), sarilumab, an anti- IL- 6R antibody, showed 
efficacy in patients who had an IR to TCZ, another IL- 6Ri,67 
and in a study published after this SLR, TNFi showed efficacy 
after failure of JAKi.129
A strategy trial comparing treatment aimed at clinical 
remission to therapy aimed at remission by MRI showed no 
difference in clinical outcomes, but more adverse events and 
more costs in the imaging group, further confirming that 
stringent clinical remission is a sufficient treatment target and 
that imaging remission not only fails to convey better effi-
cacy, but may constitute a potentially dangerous and costly 
overtreatment.6
Tapering studies revealed that dose reduction of JAKi and 
bDMARDs is feasible and that when starting dose reduction in 
sustained stringent remission less patients flare when compared 
with start of tapering just in sustained low disease activity.125 
Importantly, patients who flare can mostly (70%–80%) regain 
their prior good response.
The results of this SLR were presented to the task force and, 
together with the safety SLR,8 formed the basis for the update of 
the EULAR RA management recommendations.
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